Mills Biopharmaceuticals, LLC

A subsidiary of Core Oncology, Mills Biopharmaceuticals, LLC (Mills) manufactures ProstaSeed® Iodine 125 brachytherapy seeds for the treatment of prostate cancer. Founded in 1992 and based in Oklahoma City, Oklahoma, Mills is the second largest supplier of Iodine 125 seeds.

Mills' state-of-the-art 25,000 square foot manufacturing facility features highly automated machines and advanced manufacturing systems. With the capacity to meet the worldwide market demand for prostate brachytherapy seeds, Mills continues to enhance its manufacturing capabilities.

Along with its unparalleled manufacturing know-how, Mills will be Core Oncology's hub for future research and development activities. The combined R&D efforts of Core Oncology and Mills will result in a broader offering of products that improve patient outcomes and make prostate brachytherapy procedures more efficient, while increasing radiation safety.

A hallmark of Mills manufacturing capabilities is its proven dedication to quality assurance.  Mills complies with all state, federal, and international medical device manufacturing regulations and has received certification to ISO 9001:2000, ISO 13485:2003, as well as ISO 13485:1996 CMDCAS (for the Canadian Medical Device regulation).  In addition, ProstaSeed sources receive 100% inspection and are 100% assayed, ensuring they're delivered to physicians with the highest level of quality assurance.

Core Oncology holds a strong leadership position in the brachytherapy market, and its acquisition of Mills will enable it to expand into new segments and product applications within the global brachytherapy market. Through advanced manufacturing and aggressive R&D efforts, Core Oncology looks forward to offering physicians an increasing array of products that simplify and improve prostate brachytherapy procedures.